Gastroesophageal Reflux Disease Symptom Severity, Proton Pump Inhibitor Use, and Esophageal Carcinogenesis | Esophageal Disease | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.  N Engl J Med. 1999;340(11):825-83110080844PubMedGoogle ScholarCrossref
2.
Chow WH, Blot WJ, Vaughan TL,  et al.  Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.  J Natl Cancer Inst. 1998;90(2):150-1559450576PubMedGoogle ScholarCrossref
3.
Lieberman DA, Oehlke M, Helfand M.Gastroenterology Outcomes Research Group in Endoscopy.  Risk factors for Barrett's esophagus in community-based practice: GORGE consortium.  Am J Gastroenterol. 1997;92(8):1293-12979260792PubMedGoogle Scholar
4.
Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.  Am J Gastroenterol. 1997;92(2):212-2159040193PubMedGoogle Scholar
5.
Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma.  Cancer Epidemiol Biomarkers Prev. 1995;4(2):85-927742727PubMedGoogle Scholar
6.
Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology.  J Natl Med Assoc. 2005;97(11):1471-147816334494PubMedGoogle Scholar
7.
Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review.  Gastroenterology. 2002;122(1):26-3311781277PubMedGoogle ScholarCrossref
8.
Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus.  Am J Gastroenterol. 1997;92(1):27-318995932PubMedGoogle Scholar
9.
Sampliner RE.Practice Parameters Committee of the American College of Gastroenterology.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus.  Am J Gastroenterol. 2002;97(8):1888-189512190150PubMedGoogle ScholarCrossref
10.
Sampliner RE.Practice Parameters Committee of the American College of Gastroenterology.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus.  Am J Gastroenterol. 1998;93(7):1028-10329672324PubMedGoogle ScholarCrossref
11.
Wang KK, Sampliner RE.Practice Parameters Committee of the American College of Gastroenterology.  Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.  Am J Gastroenterol. 2008;103(3):788-79718341497PubMedGoogle ScholarCrossref
12.
Velanovich V. The development of the GERD-HRQL symptom severity instrument.  Dis Esophagus. 2007;20(2):130-13417439596PubMedGoogle ScholarCrossref
13.
Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI).  J Voice. 2002;16(2):274-27712150380PubMedGoogle ScholarCrossref
14.
Jobe BA, Hunter JG, Chang EY,  et al.  Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison.  Am J Gastroenterol. 2006;101(12):2693-270317227516PubMedGoogle ScholarCrossref
15.
Velanovich V. Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease.  J Gastrointest Surg. 1998;2(2):141-1459834409PubMedGoogle ScholarCrossref
16.
Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the Health-Related Quality of Life score and physiologic parameters.  Am Surg. 1998;64(7):649-6539655276PubMedGoogle Scholar
17.
Wallner B, Sylvan A, Janunger K-G. Endoscopic assessment of the “Z-line” (squamocolumnar junction) appearance: reproducibility of the ZAP classification among endoscopists.  Gastrointest Endosc. 2002;55(1):65-6911756917PubMedGoogle ScholarCrossref
18.
Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia.  Am J Gastroenterol. 2000;95(11):3089-309611095322PubMedGoogle ScholarCrossref
19.
Levine DS, Blount PL, Rudolph RE, Reid BJ. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus.  Am J Gastroenterol. 2000;95(5):1152-115710811320PubMedGoogle ScholarCrossref
20.
Lewin KJ, Appleman HD. Tumors of the esophagus and stomach. In: Atlas of Tumor Pathology. Vol 18. Washington, DC: Armed Forces Institute of Pathology, American Registry of Pathology; 1996
21.
Nasseri-Moghaddam S, Razjouyan H, Nouraei M,  et al.  Inter- and intra-observer variability of the Los Angeles classification: a reassessment [published correction appears in Arch Iran Med. 2007;10(3):429].  Arch Iran Med. 2007;10(1):48-5317198454PubMedGoogle Scholar
22.
Lundell LR, Dent J, Bennett JR,  et al.  Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification.  Gut. 1999;45(2):172-18010403727PubMedGoogle ScholarCrossref
23.
Hosmer DW, Lemeshow S. Applied Logistic Regression. Hoboken, NJ: John Wiley & Sons, Inc; 2000
24.
Pilotto A, Franceschi M, Leandro G,  et al.  Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients.  J Am Geriatr Soc. 2006;54(10):1537-154217038071PubMedGoogle ScholarCrossref
25.
Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.  Cancer. 1998;83(10):2049-20539827707PubMedGoogle ScholarCrossref
26.
Brown LM, Devesa SS, Chow W-H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.  J Natl Cancer Inst. 2008;100(16):1184-118718695138PubMedGoogle ScholarCrossref
27.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007.  CA Cancer J Clin. 2007;57(1):43-6617237035PubMedGoogle ScholarCrossref
28.
Korkmaz M, Tarhan E, Unal H, Selcuk H, Yilmaz U, Ozluoglu L. Esophageal mucosal sensitivity: possible links with clinical presentations in patients with erosive esophagitis and laryngopharyngeal reflux.  Dig Dis Sci. 2007;52(2):451-45617219066PubMedGoogle ScholarCrossref
29.
Fass R, Yalam JM, Camargo L, Johnson C, Garewal HS, Sampliner RE. Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett's esophagus.  Dig Dis Sci. 1997;42(9):1853-18589331147PubMedGoogle ScholarCrossref
30.
Grade A, Pulliam G, Johnson C, Garewal H, Sampliner RE, Fass R. Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium.  Am J Gastroenterol. 1997;92(11):2040-20439362188PubMedGoogle Scholar
31.
Niemantsverdriet EC, Timmer R, Breumelhof R, Smout AJ. The roles of excessive gastro-oesophageal reflux, disordered oesophageal motility and decreased mucosal sensitivity in the pathogenesis of Barrett's oesophagus.  Eur J Gastroenterol Hepatol. 1997;9(5):515-5199187887PubMedGoogle ScholarCrossref
32.
Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO.  Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.  Gastroenterology. 2001;120(7):1599-160611375942PubMedGoogle ScholarCrossref
33.
Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.  Aliment Pharmacol Ther. 2004;20(6):637-64315352912PubMedGoogle ScholarCrossref
34.
Vallböhmer D, DeMeester SR, Peters JH,  et al.  Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus.  Dis Esophagus. 2006;19(4):260-26616866857PubMedGoogle ScholarCrossref
35.
Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.  Gastroenterology. 1999;117(2):327-33510419913PubMedGoogle ScholarCrossref
36.
Burnat G, Rau T, Elshimi E, Hahn EG, Konturek PC. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line.  Scand J Gastroenterol. 2007;42(12):1460-146517852856PubMedGoogle ScholarCrossref
37.
Kazumori H, Ishihara S, Rumi MAK, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium.  Gut. 2006;55(1):16-2516118348PubMedGoogle ScholarCrossref
38.
Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux.  Am J Gastroenterol. 2001;96(7):2005-201211467625PubMedGoogle ScholarCrossref
39.
Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD?  Gastrointest Endosc. 2003;58(5):661-67014595298PubMedGoogle ScholarCrossref
40.
Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans.  J Clin Gastroenterol. 2001;33(4):306-30911588545PubMedGoogle ScholarCrossref
41.
Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia.  Ann Intern Med. 1999;130(11):883-89010375336PubMedGoogle Scholar
42.
Salem SB, Kushner Y, Marcus V, Mayrand S, Fallone CA, Barkun AN. The potential impact of contemporary developments in the management of patients with gastroesophageal reflux disease undergoing an initial gastroscopy.  Can J Gastroenterol. 2009;23(2):99-10419214284PubMedGoogle Scholar
43.
Nandurkar S, Locke GR III, Murray JA,  et al.  Rates of endoscopy and endoscopic findings among people with frequent symptoms of gastroesophageal reflux in the community.  Am J Gastroenterol. 2005;100(7):1459-146515984966PubMedGoogle ScholarCrossref
44.
Dickman R, Mattek N, Holub J, Peters D, Fass R. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database.  Am J Gastroenterol. 2007;102(6):1173-117917378910PubMedGoogle ScholarCrossref
45.
Fan X, Snyder N. Prevalence of Barrett's esophagus in patients with or without GERD symptoms: role of race, age, and gender.  Dig Dis Sci. 2009;54(3):572-57718654849PubMedGoogle ScholarCrossref
46.
Poelmans J, Feenstra L, Demedts I, Rutgeerts P, Tack J. The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms.  Am J Gastroenterol. 2004;99(8):1419-142615307853PubMedGoogle ScholarCrossref
47.
Toruner M, Soykan I, Ensari A, Kuzu I, Yurdaydin C, Özden A. Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms.  J Gastroenterol Hepatol. 2004;19(5):535-54015086597PubMedGoogle ScholarCrossref
48.
Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County.  Cancer Epidemiol Biomarkers Prev. 2009;18(2):526-53319190141PubMedGoogle ScholarCrossref
49.
García Rodríguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.  Gut. 2006;55(11):1538-154416785284PubMedGoogle ScholarCrossref
50.
Okamoto K, Iwakiri R, Mori M,  et al.  Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects.  Dig Dis Sci. 2003;48(12):2237-224114714607PubMedGoogle ScholarCrossref
51.
Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment.  Clin Gastroenterol Hepatol. 2004;2(8):665-66815290658PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    Proton Pump Inhibitors And Esophageal Adenocarcinoma
    Paul J. Rosch, MD | Clinical Professor of Medicine and Psychiatry New York Medical College
    The finding by Nason et al1 that patients who took more proton pump inhibitors (PPIs) to prevent or treat GERD had higher rates of esophageal adenocarcinoma, supports the view that in addition to osteoporotic fractures and Clostridium difficile infections, protracted use of these drugs could also increase risk of cancer.2,3 In addition, the unexplained dramatic rise in this previously uncommon malignancy mirrors the increased use of PPIs. One possibility is that pancreatic enzymes, which would normally be inactivated by hydrochloric acid, are now able to cause esophageal irritation and dysplasia. As also previously suggested, "this may not develop from direct superficial injury but rather from stimulation of esophageal cytokines that attract inflammatory cells to submucosal tissues."2 GERD patients usually show no mucosal damage on endoscopy, and in animal studies, no gross or microscopic evidence of inflammation in the esophageal mucosa was seen following exposure to acute stress, hydrochloric acid, ethanol, aspirin, or prednisolone.4 The earliest changes seen much later were dilated esophageal epithelial intercellular spaces that were not prevented by pretreatment with esomeprazole (Nexium), suggesting that they were not due to acid reflux.5
    While PPI's were originally used for only 4-6 weeks to treat GERD, many patients take them for much longer, especially those without GERD in whom biopsies show dysplastic changes consistent with Barrett's esophagus. These and others may be prescribed PPIs perpetually, despite the lack of evidence that this prevents or delays the development of esophageal adenocarcinoma. Surgery for GERD similarly does not reduce risk for this malignancy, further highlighting the need for more long-term studies.
    References: 1. Nason KS, Wichienkuer PP, Awais O, et al. Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg. 2011; 146 (7): 851-858. 2. Rosch PJ. Could Proton Pump Inhibitors Cause Cancer? Arch Intern Med. 2010; 170(19):1775-1776. 3. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009; 100(9):1503-1507. 4. Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137(5):1776-1784. 5. Zhang DH, Zhou LY, Dong XY, et al. Factors influencing intercellular spaces in the rat esophageal epithelium. World J Gastroenterol. 2010;16(9):1063-1069

    Conflict of Interest: None declared
    CONFLICT OF INTEREST: None Reported
    READ MORE
    Original Article
    July 2011

    Gastroesophageal Reflux Disease Symptom Severity, Proton Pump Inhibitor Use, and Esophageal Carcinogenesis

    Author Affiliations

    Author Affiliations: Division of Thoracic and Foregut Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania (Drs Nason, Awais, Schuchert, Luketich, and Jobe); and Departments of Public Health and Preventive Medicine (Dr Wichienkuer), Surgery (Drs O’Rourke, Hunter, and Jobe), and Informatics and Clinical Epidemiology (Dr Morris), Oregon Health & Science University, Portland.

    Arch Surg. 2011;146(7):851-858. doi:10.1001/archsurg.2011.174
    Abstract

    Hypothesis Screening for esophageal adenocarcinoma has focused on identifying Barrett esophagus (BE) in patients with severe, long-standing symptoms of gastroesophageal reflux disease (GERD). Unfortunately, 95% of patients who develop esophageal adenocarcinoma are unaware of the presence of BE before their cancer diagnosis, which means they never had been selected for screening. One possible explanation is that no correlation exists between the severity of GERD symptoms and cancer risk. We hypothesize that severe GERD symptoms are not associated with an increase in the prevalence of BE, dysplasia, or cancer in patients undergoing primary endoscopic screening.

    Design Cross-sectional study.

    Setting University hospital.

    Patients A total of 769 patients with GERD.

    Interventions Primary screening endoscopy performed from November 1, 2004, through June 7, 2007.

    Main Outcomes Measures Symptom severity, proton pump inhibitor therapy, and esophageal adenocarcinogenesis (ie, BE, dysplasia, or cancer).

    Results Endoscopy revealed adenocarcinogenesis in 122 patients. An increasing number of severe GERD symptoms correlated positively with endoscopic findings of esophagitis (odds ratio, 1.05; 95% confidence interval, 1.01-1.09). Conversely, an increasing number of severe GERD symptoms were associated with decreased odds of adenocarcinogenesis (odds ratio, 0.94; 95% confidence interval, 0.89-0.98). Patients taking proton pump inhibitors were 61.3% and 81.5% more likely to have adenocarcinogenesis if they reported no severe typical or atypical GERD symptoms, respectively, compared with patients taking proton pump inhibitors, who reported that all symptoms were severe.

    Conclusions Medically treated patients with mild or absent GERD symptoms have significantly higher odds of adenocarcinogenesis compared with medically treated patients with severe GERD symptoms. This finding may explain the failure of the current screening paradigm in which the threshold for primary endoscopic examination is based on symptom severity.

    ×